Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Hernandez, Ubaldo Benitez
MetadataShow full item record
CitationModelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020. 2018, 68 (5):932-939 J. Hepatol.
AbstractIn Iceland a nationwide program has been launched offering direct-acting antiviral (DAA) treatment for everyone living with hepatitis C virus (HCV). We estimate (i) the time and treatment scale-up required to achieve the World Health Organization's HCV elimination target of an 80% reduction in incidence; and (ii) the ongoing frequency of HCV testing and harm reduction coverage among people who inject drugs (PWID) required to minimize the likelihood of future HCV outbreaks occurring.
We used a dynamic compartmental model of HCV transmission, liver disease progression and the HCV cascade of care, calibrated to reproduce the epidemic of HCV in Iceland. The model was stratified according to injecting drug use status, age and stage of engagement. Four scenarios were considered for the projections.
The model estimated that an 80% reduction in domestic HCV incidence was achievable by 2030, 2025 or 2020 if a minimum of 55/1,000, 75/1,000 and 188/1,000 PWID were treated per year, respectively (a total of 22, 30 and 75 of the estimated 400 PWID in Iceland per year, respectively). Regardless of time frame, this required an increased number of PWID to be diagnosed to generate enough treatment demand, or a 20% scale-up of harm reduction services to complement treatment-as-prevention incidence reductions. When DAA scale-up was combined with annual antibody testing of PWID, the incidence reduction target was reached by 2024. Treatment scale-up with no other changes to current testing and harm reduction services reduced the basic reproduction number of HCV from 1.08 to 0.59, indicating that future outbreaks would be unlikely.
HCV elimination in Iceland is achievable by 2020 with some additional screening of PWID. Maintaining current monitoring and harm reduction services while providing ongoing access to DAA therapy for people diagnosed with HCV would ensure that outbreaks are unlikely to occur once elimination targets have been reached.
In Iceland, a nationwide program has been launched offering treatment for the entire population living with hepatitis C virus (HCV). A mathematical model was used to estimate the additional health system requirements to achieve the HCV elimination targets of the World Health Organization (WHO), as well as the year that this could occur. With some additional screening of people who inject drugs, Iceland could reach the WHO targets by 2020, becoming one of the first countries to achieve HCV elimination. The model estimated that once elimination targets were reached, maintaining current monitoring and harm reduction services while providing ongoing access to DAA therapy for people diagnosed with HCV would ensure that future HCV outbreaks are unlikely to occur.
DescriptionTo access publisher's full text version of this article click on the hyperlink below
RightsArchived with thanks to Journal of hepatology
- Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.
- Authors: Scott N, Doyle JS, Wilson DP, Wade A, Howell J, Pedrana A, Thompson A, Hellard ME
- Issue date: 2017 Sep
- Is hepatitis C virus elimination possible among people living with HIV and what will it take to achieve it?
- Authors: Martin NK, Boerekamps A, Hill AM, Rijnders BJA
- Issue date: 2018 Apr
- Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model.
- Authors: Heffernan A, Cooke GS, Nayagam S, Thursz M, Hallett TB
- Issue date: 2019 Mar 30
- Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there?
- Authors: Grebely J, Dore GJ, Morin S, Rockstroh JK, Klein MB
- Issue date: 2017 Jul 28
- Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?
- Authors: Lima VD, Rozada I, Grebely J, Hull M, Lourenco L, Nosyk B, Krajden M, Yoshida E, Wood E, Montaner JS
- Issue date: 2015